safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study [published online January 1, 2018]. Cephalalgia. doi: 10.1177/0333102418788347.
home / authors / safety-of-erenumab-amg334-in-chronic-migraine-patients-with-prior-preventive-treatment-failure-a-subgroup-analysis-of-a-randomized-double-blind-placebo-controlled-study-published-online-january-1-2018-cephalalgia-doi-101177-0333102418788347
Articles
August 9th 2018
Ashina M, Tepper S, Brandes JL, et al. Efficacy safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study [published online January 1, 2018]. Cephalalgia. doi: 10.1177/0333102418788347.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 21st 2024 | Updated: November 22nd 2024
Polygenic Risk Scores Can Identify Patients Who Should Receive IOP-Lowering Treatment
